glp-1 drugs and alzheimer's Details of failed studies cast pall on Novo Nordisk's as treatment GLP-1 Agonists: Obesity & Alzheimer's

Merck, Rome, Italy

Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management

That said, evidence-based oral approaches can produce meaningful change for many people and may come with fewer systemic side effects

Taken together, these results position retatrutide as a breakthrough in comprehensive metabolic care, moving far beyond the limitations of current weight-loss and diabetes medications

The safety of microdosing GLP-1 medications is not well-established, and there is limited scientific research on long-term safety or effectiveness

doi: 10.1016/j.molmet.2019.09.010 42 AndrikouETsioufisCAndrikouILeontsinisITousoulisDPapanasN